Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Astria Therapeutics Q3 EPS $(0.87) Down From $(0.61) YoY

Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.87) per share. This is a 42.62 percent decrease over losses of $(0.61) per share from the same period last year.
byBenzinga Newsdesk
November 10, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.87) per share. This is a 42.62 percent decrease over losses of $(0.61) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

What’s Going On With Medical Properties Trust Stock?

By Erica Kollmann
April 15, 10:15 AM
Medical Properties Trust (MPT) announced on Friday that it has sold its interests in five Utah hospitals to a newly formed joint venture while MPT retained an approximate 25% interest in the new venture. The venture also placed new non-recourse secured financing, providing $190 million of additional cash to MPT based on its share of the proceeds. 

MPW

Read More

Melinta Therapeutics & Cidara Therapeutics Announce Publication Of Pooled Data From Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial Of REZZAYO For The Treatment Of Candidemia & Invasive Candidiasis In The Lancet ID

By Benzinga Newsdesk
December 5, 10:08 AM
Publication reaffirms the proven efficacy and safety of rezafungin dosed once-weekly versus a current standard of care echinocandin dosed once-dailyMelinta Therapeutics, LLC and Cidara Therapeutics, Inc. (NASDAQ:CDTX)

CDTX